Best Supplements to Take With ACE-031

ACE-031 Opens the Door. Your Nutritional Foundation Has to Walk Through It.

ACE-031 is not an anabolic compound in the way most people think about anabolics. It does not add a growth signal. It removes a growth brake.

Here is what that means. Your body produces proteins called myostatin and activin A whose job, in part, is to keep muscle from getting too large. They do this by binding to a receptor on muscle cells and triggering a chain of events that tells those cells to stop growing. ACE-031 is an engineered protein that circulates in the bloodstream and physically intercepts those inhibitory proteins before they can reach the receptor. With the brake removed, the cells responsible for muscle repair and growth are free to do far more than they could before.

The clinical results from a single dose were notable. In a Phase 1 trial in women who were not exercising and not changing their diet, one injection produced measurable increases in lean body mass within 29 days. The compound also raised bone-formation markers within two weeks of dosing.

What makes ACE-031 unlike nearly everything it gets compared to is the breadth of what it catches. Most next-generation myostatin blockers in development are selective. Apitegromab, for example, targets only the inactive precursor form of myostatin and nothing else. ACE-031 acts more like a net than a sniper rifle, intercepting myostatin, activin A, activin B, and several related proteins simultaneously. That broader reach is likely why the anabolic signal was so strong. It is also why the compound ran into serious trouble in Phase 2 trials.

Some of the proteins ACE-031 intercepts are critical for maintaining the structural integrity of blood vessel walls, keeping them stable and intact. Removing them disrupted the body's ability to maintain that stability in a way that produced nosebleeds, dilated surface blood vessels called telangiectasias, and gum bleeding. These events were significant enough that Acceleron Pharma halted the program. ACE-031 is not approved by any regulatory authority, and anyone using it outside a clinical context is doing so at meaningful and well-documented risk.

That vascular safety profile is what separates ACE-031 from every compound it is commonly grouped with. Bimagrumab blocks the relevant receptor at the cell surface rather than in the bloodstream, and its vascular risk profile is substantially lower because it does not capture the same vessel-wall signaling proteins. Apitegromab's myostatin specificity means it does not touch those proteins at all. ACE-031 is the outlier, and that outlier status shapes everything downstream, including which supplements matter and what to watch for.

Now, the nutritional argument. ACE-031 removes inhibition. It does not provide substrate. The growth it enables still requires protein to build from, energy to train with, and the hormonal environment that determines whether newly acquired tissue is actually maintained. An unsupported body running ACE-031 is like a construction crew given the green light but no materials. The Phase 1 results came from women with no exercise intervention and no diet change. That demonstrates just how powerful the signal is. But the full ceiling of what that signal can produce requires meeting it with the right nutritional foundation.

The Supplements That Matter Most on ACE-031

There are no dose numbers on this page. The right amount of each supplement depends on your actual protocol, your training load, how long you have been running ACE-031, and what your bloodwork shows. MyPeptidePal works that out for you specifically.

What ACE-031's Mechanism Actually Needs to Execute

ACE-031 itself requires no nutrient cofactors in the traditional sense. The compound is a protein that works by physically binding other proteins in the bloodstream. That reaction does not depend on vitamins or minerals the way an enzyme pathway does. When people ask what ACE-031 needs to work, the honest answer is that the compound functions independently of dietary inputs.

But that is the wrong question. The right question is what the muscle tissue ACE-031 is trying to grow needs to grow.

Protein and EAAs (Leucine-Rich Sources)

This is the single most important nutritional variable when running ACE-031, and it carries double-duty status: it is both the cofactor the growth mechanism requires and the primary tool for preserving what gets built.

ACE-031 works by releasing the brake on the cell's master switch for building new muscle tissue. Think of it as a green light for the construction crew that assembles new muscle from raw materials. That switch has its own prerequisite: it requires leucine, a specific essential amino acid, as a direct chemical sensor before it activates. Without leucine present, the switch does not turn on regardless of how thoroughly the myostatin brake has been cleared.

Without adequate protein overall, there is no raw material to assemble into muscle tissue regardless of how loud the anabolic signal is. The cells get the message to grow. There is nothing to grow with.

This is not a general nutrition point dressed up as a mechanism argument. ACE-031 specifically releases that growth switch from inhibition. Leucine specifically activates it. Those two facts together mean protein intake is upstream of whether the compound's mechanism translates into actual tissue, not merely supportive of it.

Leucine-rich protein sources include whey protein and eggs. EAA blends providing the full set of essential amino acids, with leucine prominent among them, are the most direct way to ensure the pathway has what it needs around training. The evidence for adequate protein intake in the context of muscle hypertrophy is backed by extensive clinical trial data. No trial has specifically tested protein intake alongside ACE-031, but the underlying biochemistry is as well-established as nutrition science gets.

Because protein also preserves the lean mass ACE-031 builds and ensures the compound's signal is not wasted on tissue that is later broken down, it is the only item on this list that earns the double-duty designation.

Creatine Monohydrate

ACE-031 enables more hypertrophy. Hypertrophy requires training. Training requires energy. Creatine determines how much high-intensity energy is available.

Muscle cells store a fast-energy molecule called phosphocreatine as their quickest reserve for explosive and high-intensity effort. When you are training hard enough, often enough, and with enough volume to drive the muscle growth that ACE-031 has created the capacity for, phosphocreatine is the fuel system you are drawing from. Creatine supplementation raises those stores in muscle, extending how much work the cell can do before running out of fast energy.

The connection to ACE-031 is practical rather than biochemical. ACE-031 does not directly interact with the creatine energy system. What it does is create a ceiling on muscle growth that is much higher than normal. Reaching that ceiling requires training quality and volume. Creatine supports both by keeping the energy system fueled for hard efforts.

The evidence for creatine monohydrate is among the strongest in all of sports nutrition, backed by decades of controlled trials showing reliable improvements in strength and high-intensity performance. No trial has studied creatine alongside ACE-031, and none is likely to given the compound's regulatory status. The rationale here is mechanistic and extrapolated from creatine's well-established general effects.

Building the Right Environment for ACE-031's Signal

ACE-031 produces lean mass gains and bone-formation effects simultaneously, which is unusual. Most anabolic signals are selective. The compound's broad capture of inhibitory proteins means it acts on muscle and bone together, and the supplements that support the bone side of that equation are genuinely relevant here in a way they would not be on a pure muscle-growth compound.

Vitamin D

ACE-031's Phase 1 clinical data showed significant increases in bone-formation markers within two weeks of a single dose. The bone-building signal is real and fast. But the signal reaching bone cells and actual mineralized bone being deposited are two different things. Vitamin D is what links them.

The body absorbs calcium from food with the help of vitamin D. Without enough of it, calcium cannot move from the gut into circulation. Without calcium in circulation, the cells that lay down new bone, called osteoblasts (the cells responsible for building and mineralizing bone), cannot complete their work regardless of how strongly ACE-031 is stimulating them. Vitamin D is, in this specific context, the last step between ACE-031's bone-building signal and bone that is actually there.

There is a second reason vitamin D matters here. Research has consistently shown that vitamin D influences muscle fiber composition and the behavior of satellite cells, which are the repair and growth cells that live alongside muscle fibers. ACE-031 releases satellite cells from myostatin suppression, which is their primary growth constraint. Vitamin D supports their function. Those two things are complementary rather than redundant.

Vitamin D absorbs better alongside dietary fat, which is worth knowing when deciding when to take it. Vitamin D deficiency is genuinely common across the general population. The evidence for its role in bone metabolism is clinical, backed by extensive trial data. Its specific relevance to ACE-031's bone effects is mechanistic rather than directly studied.

Zinc

Zinc earns its place here through two routes that both matter in the context of ACE-031.

The first is hormonal. Zinc deficiency suppresses testosterone and IGF-1, two anabolic hormones that work through pathways adjacent to and overlapping with the growth switch ACE-031 is targeting. Low zinc is a quiet drag on the anabolic environment that ACE-031 cannot compensate for, because the compound operates upstream of those hormone-dependent inputs rather than in parallel with them.

The second is satellite cells. These are the muscle stem cells whose proliferation ACE-031 un-suppresses by blocking myostatin. Zinc is involved in the enzymatic activity that drives satellite cell division and the broader cellular repair processes those cells carry out. Supporting satellite cell function is supporting the exact cell population ACE-031 is acting on.

There is also a practical note specific to ACE-031's safety profile. The compound's vascular side effects involve changes to mucosal surfaces, including gum bleeding and nosebleeds. Zinc plays a well-established role in mucosal integrity and wound healing. Whether zinc supplementation meaningfully mitigates ACE-031's vascular effects is unknown, as there is no clinical data for this specific application, but supporting mucosal health while running a compound known for mucosal fragility is a defensible practice.

The evidence for zinc's role in testosterone support and protein synthesis is backed by clinical data in deficient populations. Its application in the ACE-031 context is partly mechanistic and partly extrapolated from that broader evidence base.

Vitamin K2

ACE-031 raises osteocalcin, a protein secreted by bone-building cells that also functions as a hormone involved in insulin sensitivity and muscle function. For osteocalcin to carry out its bone-specific job, it has to undergo a chemical activation step that makes the protein functional, and that activation requires vitamin K2. Without K2, elevated osteocalcin remains in an inactive form that cannot properly direct calcium into bone matrix. ACE-031 lifts the production signal; K2 determines whether the resulting protein is actually functional.

This is the most directly compound-specific rationale for K2 on this list. ACE-031 produces a meaningful, measured rise in osteocalcin within two weeks of dosing. That is the setup. K2 is what completes it.

K2 also activates a protein that helps regulate vascular calcification and supports blood vessel wall integrity. Whether this provides any meaningful offset to ACE-031's vascular disruption is not established by clinical data. The mechanism is plausible; the application to ACE-031's specific vascular profile is theoretical. The bone-osteocalcin argument is the one that genuinely earns K2 its place on this list.

The clinical evidence for K2 in bone metabolism is reasonably well-supported in controlled studies. Its application here is partly mechanistic.

Holding What ACE-031 Builds

Resistance Training

This is listed because it is required. Not recommended. Required.

The ACE-031 trial data showing lean mass gains came from subjects who were not training. The compound produces measurable growth even without exercise, which is part of what made it scientifically interesting for conditions like muscular dystrophy. But gains produced without training are substantially smaller than what the compound's mechanism is capable of generating. Evidence from myostatin biology broadly shows that muscle acquired without mechanical stimulus is less functional, less dense, and more vulnerable to loss after the compound is discontinued.

ACE-031 removes the molecular brake on muscle growth. Resistance training is the signal that tells the muscle where that growth should go and ensures the tissue that forms is structurally integrated and mechanically capable. Without it, ACE-031's release of growth pathways is partially wasted on tissue that will not be reinforced by use. With it, the compound's signal and the mechanical stimulus of training work together to produce results neither can fully achieve alone.

This is not a supplement, and its place here reflects that it functions as both a result-preservation tool and a practical requirement for realizing the compound's full potential. As noted in the cofactors section, protein pulls double duty as the result-preservation tool that locks in what resistance training and ACE-031 produce together. Building the tissue and then failing to supply the maintenance substrate for it is one of the clearest ways to leave gains on the table.

What to Watch for and What to Avoid

Bleeding Events and Blood-Thinning Compounds

This is the lead caution.

ACE-031's Phase 2 trials were halted specifically because of vascular adverse events: nosebleeds, telangiectasias (small dilated blood vessels visible at the skin surface), and gum bleeding. These are not rare side effects. They are the reason the program stopped. They result from ACE-031 intercepting proteins the body uses to maintain the structural integrity of blood vessel walls, keeping them stable and intact. With those signals blocked, the body's ability to maintain that stability is disrupted.

Anyone running ACE-031 must not combine it with anticoagulant medications such as warfarin, apixaban, or rivaroxaban. The combination of compound-induced vascular fragility and medication-induced clotting suppression creates a compounded hemorrhagic risk that goes well beyond either alone. This requires medical supervision, not a supplement adjustment.

The same concern applies at somewhat lower severity to antiplatelet medications including high-dose aspirin, clopidogrel, and ticagrelor. NSAIDs such as ibuprofen and naproxen impair platelet function and should be used cautiously.

Among supplements, fish oil that enters antiplatelet territory has mild antiplatelet activity that becomes relevant in this context. High-dose vitamin E similarly inhibits platelet aggregation. Ginkgo biloba carries antiplatelet properties and should be avoided. At moderate doses, fish oil's anti-inflammatory benefits do not pose meaningful added risk. The concern is specifically with doses that cross into antiplatelet territory.

Any nosebleed, skin vascular change, or gum bleeding while running ACE-031 should be treated as a signal to stop, not to manage through. These symptoms are not coincidental findings in someone running this compound. The mechanism is understood well enough that their appearance is informative.

Erythropoiesis and Iron

ACE-031 inhibits activin A, which normally acts as a brake on the later stages of red blood cell production. Removing that brake means ACE-031 may raise hemoglobin and hematocrit over time. This is relevant to iron in two directions.

First, increased red blood cell production consumes iron. Users with borderline iron stores, especially those doing intensive training, may find ferritin declining over weeks to months, not because ACE-031 directly reduces iron absorption, but because the body is using more iron than before. Hemoglobin may look normal while ferritin quietly falls, masking the depletion until it affects performance.

Second, iron supplementation without a confirmed deficiency is not appropriate here. If ACE-031 is already raising hemoglobin, adding iron risks contributing to elevated hematocrit or iron overload. Ferritin and hemoglobin should be checked before and during use, and iron should only be supplemented if ferritin is confirmed low by bloodwork.

Combining ACE-031 with erythropoiesis-stimulating agents creates additive pressure on red blood cell production and raises the risk of polycythemia and the blood-viscosity complications that accompany it. This combination is a serious concern.

Compounds That Affect the Same Signaling Network

ACE-031 broadly disrupts signaling from a large family of proteins that control cell growth and repair. Experimental compounds that also modify this network, including investigational inhibitors and related research chemicals targeting these same pathways, create unpredictable additive signaling disruption when combined with ACE-031. This is a mechanism-based concern with no clinical data to quantify it, which makes it more concerning rather than less.

Frequently Asked Questions

How much of each supplement should I take with ACE-031?

There are no dose numbers on this page, and that is deliberate. The right amounts of protein, creatine, vitamin D, zinc, and vitamin K2 depend on your current bloodwork, your training volume, your body weight, and the specifics of your ACE-031 protocol. MyPeptidePal takes those inputs and builds a personalized plan, which is exactly the job these general guides cannot do on their own.

Which blood markers should I monitor while running ACE-031?

Hemoglobin and hematocrit are the most important, because ACE-031 may raise both by releasing the brake on red blood cell production. Ferritin should be checked alongside them, since increased red blood cell production draws on iron stores and a decline can go unnoticed when hemoglobin still looks normal. Bone-formation markers including osteocalcin and alkaline phosphatase will rise if the compound is working as intended. Vitamin D status should be confirmed before assuming the compound's bone-building signal can complete downstream mineralization.

Do any of these supplements interfere with how ACE-031 works?

None of the listed supplements block or blunt ACE-031's mechanism. Protein and creatine support the downstream environment the compound is acting on; vitamin D, zinc, and vitamin K2 maintain the structural and hormonal context. The interaction concern runs the other direction: certain supplements with antiplatelet activity at higher doses, specifically high-dose fish oil, high-dose vitamin E, ginkgo biloba, and garlic extracts, add to ACE-031's already elevated bleeding risk and should be kept at conservative doses or avoided.

Do I need to time these supplements around my ACE-031 injection?

No. ACE-031 is injected subcutaneously and works through a protein-protein interaction in the bloodstream. Its mechanism does not depend on dietary inputs, so the timing of the injection is irrelevant to when you take your supplements. Each supplement should be timed according to its own absorption characteristics: vitamin D absorbs better alongside dietary fat, creatine can be taken at any consistent daily time, and protein is most useful around training sessions.

Can I skip the supplement stack if I am eating a high-protein diet?

A nutrient-sufficient diet covers most of the ground these supplements address, which is the honest answer. A high-protein diet with adequate leucine does functionally what protein supplementation does. Sufficient sun exposure or dietary vitamin D does what a supplement does. The argument for supplementing is that meeting the elevated protein requirements ACE-031 creates through food alone is genuinely difficult for most people, and that shortfalls in vitamin D and zinc are common enough that assuming sufficiency without checking is a reasonable bet to lose. Run the bloodwork and let it answer the question rather than assuming either way.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of ACE-031 and the nutrients that support it in one place.